Segmentation of Consuming Markets of Beef

One of the tasks most difficult in the planning of marketing has been the election of the market-target. Being thus, the market segmentation reveals of great importance. The objective of this study is to discuss a market segmentation model of meat consumers. For in such a way, a bibliographical research was conducted, adopting two basic conditions: (a) the proposals of segmentation of used consuming markets in excellent scientific studies can indicate insights for the presented theoretical construction; and (b) the excellent variable in the process of purchase of the consumers must be considered in the quarrel proposal. The following excellent variable had been identified, considering the purchase process: culture, motivation, perception, health, nutritional value, pecuniary acceptability, beliefs, intention, variable, attitude, style of life and preparation of the food. This allowed the identification of four segments of consumers: Guided by Meat Protein, Guided by Health, Indifferent and Sporadic. It is concluded, therefore, the product meat can not be considered as commodity, it exists other factors, beyond the price, that have great influence on the behavior of purchase of the consumer.segmentation, meat, Consumer behavior, Food Consumption/Nutrition/Food Safety, Institutional and Behavioral Economics,

Riscos ocupacionais em idosos, catadores de materiais recicláveis, no Distrito Federal, Brasil

This study aimed to analyze the sociodemographic profile, risk factors and health conditions of elderly collectors of recyclable material who worked in an open-air garbage dump, the Structural City Dump in the Federal District, Brazil. The study is cross-sectional and data were collected from a semi-structured instrument, in which sociodemographic, epidemiological and laboratory variables of the research participants were analyzed. The survey demonstrates great vulnerability of this group, highlighting gender differences such as: 64.6% were women, 46.2% were single, 60% reported brown color, 26.2% had more than 4 children, 33.8% had no education level , 52.3 hypertensive and of these 61.9% were women; 83.1% reported exposure to risks with sharp piercing material and 61.5% to contact with decomposing garbage; 56.9% reported accidents with cuts and perforations; 70.8% contact with rodents; 83.1% reported exposure to smoke. This study suggests that the implementation of public and health policies are important to this group, as well as awareness strategies in society, in order to guarantee safe working and living conditions for the health of this population.Este trabalho objetivou analisar o perfil sociodemográfico, os fatores de risco e as condições de saúde dos idosos catadores de material reciclável que atuavam em um depósito de lixo a céu aberto, o Lixão da cidade Estrutural no Distrito Federal, Brasil. O estudo é transversal e os dados foram coletados a partir de um instrumento semiestruturado, em que foram analisadas variáveis sociodemográficas, epidemiológicas e laboratoriais dos participantes da pesquisa. A pesquisa demonstra grande vulnerabilidade deste grupo, destacando diferenças de gênero como: 64,6% eram mulheres, 46,2% solteiros, 60% referiram cor parda, 26.2 % com mais de 4 filhos, 33,8% sem nenhum grau de escolaridade, 52,3 hipertensos e destes 61,9% são mulheres; 83,1% relataram exposição a riscos com material perfuro cortante e 61,5 % ao contato com lixo em decomposição; 56,9% relataram acidentes com corte e perfuração; 70,8% contato com roedores; 83,1% relataram exposição à fumaça. Este estudo sugere que a implantação de políticas públicas e de saúde são importantes a este grupo, assim como estratégias de sensibilização da sociedade, a fim de garantir condições de trabalho e de vida seguras para a saúde desta população

POLÍTICA NACIONAL DE ATENÇÃO BÁSICA (2017): UM GOLPE POLÍTICO-IDEOLÓGICO DO CAPITAL

Para responder a integralidade da atenção, o modelo de organização do SUS escolhido pelo Ministério da Saúde (MS) foi o da Atenção Primária à Saúde (APS), posteriormente no Brasil, denominada de Atenção Básica à Saúde (ABS). O motivo da denominação ABS foi pela tentativa de se diferenciar dos modelos seletivos internacionais, apostando num modelo de APS como estratégia estruturante do sistema. Desde sua implantação, a ABS acumula períodos de evolução e estagnação, tanto no que se refere à cobertura, quanto ao modelo adotado pelas equipes. Esses movimentos estão intimamente relacionados com a macro política adotada pelo MS para a APS apontada por meio de políticas e programas propostos. Nesse sentido, este artigo teve o objetivo de analisar as principais mudanças contidas na nova Política Nacional de Atenção Básica (PNAB), publicada em 2017, a partir de seu contexto histórico e político. Os resultados demonstraram que a nova PNAB, fruto de um movimento político-ideológico hegemônico, apresenta mudanças importantes quanto à estrutura das equipes, organização do processo de trabalho e financiamento, que fragilizam a consolidação da ABS como proposta abrangente para estruturação do sistema de saúde, dificultando o desenvolvimento da integralidade da atenção; e sugere que é necessário militância e participação social para que a política de saúde de fato responda aos interesses e necessidades da população

I Diretriz brasileira de cardio-oncologia pediátrica da Sociedade Brasileira de Cardiologia

Sociedade Brasileira de Oncologia PediátricaUniversidade Federal de São Paulo (UNIFESP) Instituto de Oncologia Pediátrica GRAACCUniversidade Federal de São Paulo (UNIFESP)Universidade de São Paulo Faculdade de Medicina Instituto do Coração do Hospital das ClínicasUniversidade Federal do Rio Grande do Sul Hospital de Clínicas de Porto AlegreInstituto Materno-Infantil de PernambucoHospital de Base de BrasíliaUniversidade de Pernambuco Hospital Universitário Oswaldo CruzHospital A.C. CamargoHospital do CoraçãoSociedade Brasileira de Cardiologia Departamento de Cardiopatias Congênitas e Cardiologia PediátricaInstituto Nacional de CâncerHospital Pequeno PríncipeSanta Casa de Misericórdia de São PauloInstituto do Câncer do Estado de São PauloUniversidade Federal de São Paulo (UNIFESP) Departamento de PatologiaHospital Infantil Joana de GusmãoUNIFESP, Instituto de Oncologia Pediátrica GRAACCUNIFESP, Depto. de PatologiaSciEL

Educomunicação, Transformação Social e Desenvolvimento Sustentável

Esta publicação apresenta os principais trabalhos dos GTs do II Congresso Internacional de Comunicação e Educação nos temas Transformação social, com os artigos que abordam principalmente Educomunicação e/ou Mídia-Educação, no contexto de políticas de diversidade, inclusão e equidade; e, em Desenvolvimento Sustentável os artigos que abordam os avanços da relação comunicação/educação no contexto da educação ambiental e desenvolvimento sustentável

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Prevalência e fatores associados aos transtornos mentais comuns em residentes médicos e da área multiprofissional

OBJETIVO: Determinar a prevalência de transtornos mentais comuns (TMC) e sua associação a fatores sociodemográficos e profissionais em residentes de medicina, enfermagem, nutrição e saúde coletiva da cidade do Recife (PE). MÉTODOS: Estudo transversal foi conduzido, em 2007, envolvendo uma amostra aleatória de 178 residentes que responderam a questões sociodemográficas e sobre a formação profissional e ao Self-Reporting Questionnaire (SRQ-20). Calcularam-se as prevalências de TMC e estimaram-se as razões de prevalência (RP) e os intervalos de confiança. RESULTADOS: A prevalência total dos TMC foi de 51,1% e não se observou associação aos fatores sociodemográficos. A prevalência do evento foi 39% maior nos médicos que nos não médicos (p = 0,049) e 46% maior em residentes médicos das especialidades cirúrgicas que entre os de enfermagem, nutrição e saúde coletiva (p = 0,048). Cinco das queixas do SRQ-20 foram mais frequentes no sexo feminino (p < 0,05). CONCLUSÃO: Os dados demonstram a elevada magnitude dos TMC nessa população, principalmente nos residentes médicos, e servem para educadores e gestores de serviços de saúde no sentido de viabilizar estratégias para prevenir e recuperar a qualidade de vida dos residentes